JLPC(SH:600513) Ge Long Hui A P P·2026-02-06 09:58Core Viewpoint - The company plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB to support its strategic development and enhance its core competitiveness [1] Group 1: Capital Increase Details - The registered capital of Lianhuan (Anqing) will increase from 131.52 million RMB to 181.52 million RMB following the capital increase [1] - The capital increase will be funded through the company's own and self-raised funds, ensuring no adverse impact on the company's normal operations or cash flow [1] Group 2: Strategic Importance - This capital increase is aligned with the strategic development needs of Lianhuan (Anqing) and will provide a solid foundation for its future production and business development [1] - The company’s current financial status is stable and good, indicating that the capital increase will not harm the interests of the company or its shareholders [1]